8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2005

Illumina, Inc.

(Exact name of registrant as specified in its charter)

000-30361
(Commission File Number)

Delaware
(State or other jurisdiction of incorporation) 33-0804655
(I.R.S. Employer Identification No.)

9885 Towne Centre Drive, San Diego, CA 92121
(Address of principal executive offices, with zip code)

(858) 202-4500
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 7.01 Regulation FD Disclosure
	Item 9.01 Financial Statements and Exhibits
SIGNATURES
INDEX TO EXHIBITS
EXHIBIT 99.1

Item 7.01 Regulation FD Disclosure

     On June 29, 2005, Illumina, Inc. issued a press release, attached as Exhibit 99.1 to this Form 8-K and incorporated by reference herein, announcing the results of the Company’s 2005 Annual Meeting of Stockholders.

Item 9.01 Financial Statements and Exhibits

     (c) Exhibits.

99.1     Press release of Illumina, Inc. dated June 29, 2005.

-2-

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ILLUMINA, INC.
Date: June 29, 2005	By:	/s/ JAY T. FLATLEY
		Jay T. Flatley
		President and Chief Executive Officer

-3-

ILLUMINA, INC.

INDEX TO EXHIBITS

Exhibit Number	Description
99.1	Press Release of Illumina, Inc. dated June 29, 2005

-4-

EX-99.1

                                                                    Exhibit 99.1

                  ILLUMINA HOLDS ANNUAL MEETING OF STOCKHOLDERS


SAN DIEGO, CALIFORNIA, June 29, 2005 -- Illumina, Inc. (NASDAQ: ILMN) today
announced that the Company held its Annual Meeting of Stockholders on Tuesday,
June 28, 2005, at Illumina's principal executive office in San Diego, CA, as
scheduled. A quorum of stockholders was present in person or by proxy. All
proposals submitted to the Company's stockholders were approved, including the
reelection of two directors to the Board of Directors for three-year terms, the
ratification of Ernst & Young LLP as the Company's independent auditors for the
fiscal year ending January 1, 2006, and the adoption of the Company's 2005 Stock
and Incentive Plan.

The directors reelected to serve until the Company's 2008 Annual Meeting
are Daniel M. Bradbury, Chief Operating Officer of Amylin Pharmaceuticals, Inc.,
and John R. Stuelpnagel D.V.M., Senior Vice President and Chief Operating
Officer of Illumina.

ABOUT ILLUMINA

Illumina (www.illumina.com) is developing next-generation tools that permit
large-scale analysis of genetic variation and function. The Company's
proprietary BeadArray(TM) technology -- now used in leading genome centers
around the world -- provides the throughput, cost effectiveness and flexibility
to enable researchers in the life sciences and pharmaceutical industries to
perform the billions of tests necessary to extract medically valuable
information from advances in genomics and proteomics. This information will help
pave the way to personalized medicine.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995: this release may contain forward-looking statements that involve risks and
uncertainties. Among the important factors that could cause actual results to
differ materially from those in any forward-looking statements are the costs and
outcome of Illumina's litigation with Affymetrix, Illumina's ability to further
develop and commercialize its Infinium assay and BeadArray(TM) platform
technologies, to deploy new gene expression and genotyping products and
applications for its platform technology, to further scale oligo synthesis
output and technology to satisfy market demand deriving from the Company's
collaboration with Invitrogen, to scale, integrate and commercialize the CyVera
technology, to manufacture robust Sentrix(R) arrays and Oligator(R)
oligonucleotides, and other factors detailed in the Company's filings with the
Securities and





Exchange Commission including its recent filings on Forms 10-K and 10-Q or in
information disclosed in public conference calls, the date and time of which are
released beforehand. Illumina disclaims any intent or obligation to update these
forward-looking statements beyond the date of this release.


                                      # # #

Contacts:  Jay Flatley                       William Craumer
           President & CEO                   Director, Corporate Communications
           1.858.202.4501                    1.858.202.4667
           jflatley@illumina.com             bcraumer@illumina.com